Anemia drug 'does not improve outcomes' in heart failure patients

13 March 2013

A drug commonly used to treat anemia in heart failure patients does not improve outcomes, according to a recent study.

Researchers from Sahlgrenska Academy, University of Gothenburg, in Sweden claim that darbepoetin alfa cannot reduce risk of death from heart failure or improve health in patients with anemia.

The discovery was made when patients were given either darbepoetin alfa or a placebo and 50.7 per cent of patients with the drug experienced death from any cause or hospitalisation for worsening heart failure.

This is in contrast to 49.5 per cent of the patients given a placebo who experienced similar outcomes.

Karl Swedberg, senior professor at the Sweden-based Department of Medicine, stated: "The benefits of erythropoietin-stimulating agents (ESAs) such as darbepoetin alfa to treat patients with heart failure and anemia have been questioned due to contradictory research findings."

This study shows that darbepoetin alfa is unable to stimulate the production of red blood cells in patients with heart failure and anemia.

Posted by Philip Briggs

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)